Karyopharm - oncology

[anonymous]

What’s the over-under on RP making it past Q1 of next year? I’d say it’s even money at this point on whether he gets the boot.

If there's a God in heaven...!

 

[anonymous]

What’s the over-under on RP making it past Q1 of next year? I’d say it’s even money at this point on whether he gets the boot.

Stock down another four percent and change today.

 

[anonymous]

Not to worry...endometrial will save us...just ask anyone at the company. Do not, however, ask anyone outside the company...you won't like the answer.

 

[anonymous]

Offers have been extended. This one appears to be a top notch opportunity! Congrats to all of the offer recipients!

This aged well.

 

[anonymous]

This aged well.

Like a fine wine...better than 50% turnover, terrible IC plan that does not pay out, stock is dead, Amgen leaderships starting to settle in and impose their philosophy...but endometrial will save us.

 

[anonymous]

Stock down another four percent and change today.

Stock down again today. Peter Principle Paulson continues to deliver the goods!

 

[anonymous]

He’s done it! RP has saved the company with this deal. All hail King Richard!

 

[anonymous]

Here’s a philosophical question: If you cut a distribution deal for a drug with barely any sales have you really cut a distribution deal?

 

[anonymous]

Here’s a philosophical question: If you cut a distribution deal for a drug with barely any sales have you really cut a distribution deal?

Sure. At this point K-Pharm does not have the capital or resources to commercialize ex-US so the best alternative is to license out the drug and receive royalty payments. It’s not an uncommon structure for small cap biotechs where going at it alone in the ROW is financially prohibitive. We get the up front payment and it’s up to our exUS partner(s) to drive demand…if they do we get a bigger royalty…if they don’t we don’t so nothing ventured, nothing gained. Where it gets more complex is it may not excite acquiring suitors to have to deal with and/or unravel the royalty/partnership. Also in the off chance the drug becomes a world wide blockbuster, it typically is more financially advantages to book all the ROW revenue versus receiving a portion via a royalty payment. All in all this was the right decision for where we are at right now.

 

[anonymous]

Menarini deal makes sense but also a sign of desperation, $75M upfront for an approved cancer therapy isn't good,

 

[anonymous]

Menarini deal makes sense but also a sign of desperation, $75M upfront for an approved cancer therapy isn't good,

Ricky was a key part of the Clementia deal at Ipsen. That thing was idiocy of epic proportions. Stupid is as stupid does.

 

[anonymous]

Menarini deal makes sense but also a sign of desperation, $75M upfront for an approved cancer therapy isn't good,

There really wasn’t alternative. It’s a low volume, low revenue drug…not a lot of ROW partners where lining up to get a piece of the drug. What did you expect? Some major player coming in and dropping a big number on us?

 

[anonymous]

There really wasn’t alternative. It’s a low volume, low revenue drug…not a lot of ROW partners where lining up to get a piece of the drug. What did you expect? Some major player coming in and dropping a big number on us?

What if I told you Peter Principle Paulson is Canadian?

 

[anonymous]

What if I told you Peter Principle Paulson is Canadian?

Sorry by RP does not confirm to the Peter principle. I believe he's earned his own principle. The Dick Principle...a person promoted 2-3 levels ABOVE their incompetence. Simply by working at a large company and hiding, while climbing the corporate ladder.

 

[anonymous]

What if I told you Peter Principle Paulson is Canadian?

Fairly certain we all know that.

 

[anonymous]

Sorry by RP does not confirm to the Peter principle. I believe he's earned his own principle. The Dick Principle...a person promoted 2-3 levels ABOVE their incompetence. Simply by working at a large company and hiding, while climbing the corporate ladder.

I think you might be on to something. He was a horrible and complete failure at Ipsen and pushed out there, so you can’t even say that he was effective one level below where he finds himself now.

 

[anonymous]

I think you might be on to something. He was a horrible and complete failure at Ipsen and pushed out there, so you can’t even say that he was effective one level below where he finds himself now.

The formula for him is not uncommon. Have no life, be willing to move anywhere for any job/experience just to build your resume (even if you make equal or less money for a few years) be unwaveringly loyal right up to the point you can sabotage someone to get a rung up on the ladder, never stay in one position for more than 18-24 months so you never fall out of the ‘learning curve/honeymoon’ phase so you never really see if you are good or bad at a job=no true accountability, learn the ever important consultancy world and language to sound like you know what you are talking about, make even the simplest aspects of our business seem like the Diophantine Equation that only you can understand, take credit for all the good ideas from the agency, blame them for all the bad ones, lastly surround yourself with sycophant underlings promising them continual career development promotions for their loyalty. Never worry about managing the business…worry about managing your career. Poor organizations like ours falls prey to guys like him as we don’t know better. Good companies wouldn’t hire him for a DM job.

 

[anonymous]

The formula for him is not uncommon. Have no life, be willing to move anywhere for any job/experience just to build your resume (even if you make equal or less money for a few years) be unwaveringly loyal right up to the point you can sabotage someone to get a rung up on the ladder, never stay in one position for more than 18-24 months so you never fall out of the ‘learning curve/honeymoon’ phase so you never really see if you are good or bad at a job=no true accountability, learn the ever important consultancy world and language to sound like you know what you are talking about, make even the simplest aspects of our business seem like the Diophantine Equation that only you can understand, take credit for all the good ideas from the agency, blame them for all the bad ones, lastly surround yourself with sycophant underlings promising them continual career development promotions for their loyalty. Never worry about managing the business…worry about managing your career. Poor organizations like ours falls prey to guys like him as we don’t know better. Good companies wouldn’t hire him for a DM job.

This is a good analysis, but you could have just said he’s a lying, two-faced, backstabbing, untrustworthy weasel with no original thoughts.

 

[anonymous]

The formula for him is not uncommon. Have no life, be willing to move anywhere for any job/experience just to build your resume (even if you make equal or less money for a few years) be unwaveringly loyal right up to the point you can sabotage someone to get a rung up on the ladder, never stay in one position for more than 18-24 months so you never fall out of the ‘learning curve/honeymoon’ phase so you never really see if you are good or bad at a job=no true accountability, learn the ever important consultancy world and language to sound like you know what you are talking about, make even the simplest aspects of our business seem like the Diophantine Equation that only you can understand, take credit for all the good ideas from the agency, blame them for all the bad ones, lastly surround yourself with sycophant underlings promising them continual career development promotions for their loyalty. Never worry about managing the business…worry about managing your career. Poor organizations like ours falls prey to guys like him as we don’t know better. Good companies wouldn’t hire him for a DM job.

Well said. Unfortunately, I see this as a common theme in Pharma.

 

[anonymous]

Karyopharm might do okay if Peter Principle Paulson isn’t allowed to make any real decisions.